Jennifer A. Rymer

Sep 12, 2024 | jacc.org | Hiroki Ueyama |Kevin Kennedy |Jennifer A. Rymer |Alexander T. Sandhu

References1. "2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: executive summary". J Am Coll Cardiol . 2014;64:2645-2687. 2. "Timing, selection, modulation, and duration of P2Y12 inhibitors for patients with acute coronary syndromes undergoing PCI". JACC Cardiovasc Interv . 2023;16:1-18. 3. "Pre-treatment with oral P2Y12 inhibitors in non-ST-segment elevation acute coronary syndromes: does one size fit all?"JACC Cardiovasc Interv . 2020;13:918-920. 4.

May 8, 2024 | jamanetwork.com | Jennifer A. Rymer |Zachary K. Wegermann |Tracy Y. Wang |Shuang Li

Key PointsQuestion  What is the risk of late ventricular tachycardia (VT) and ventricular fibrillation (VF) after primary percutaneous coronary intervention (PCI) for patients with ST-segment elevation myocardial infarction (STEMI)? Findings  In this cohort study of 174 126 patients with STEMI, 8.9% of patients had VT or VF after primary PCI.

Apr 15, 2024 | ahajournals.org | Jennifer A. Rymer |Manesh R. Patel

REFERENCES1. Abu Dabrh AM, Steffen MW, Undavalli C, Asi N, Wang Z, Elamin MB, Conte MS, Murad MH. The natural history of untreated severe or critical limb ischemia.J Vasc Surg. 2015; 62:1642–51.e3. doi: 10.1016/j.jvs.2015.07.065CrossrefMedlineGoogle Scholar2. Duff S, Mafilios MS, Bhounsule P, Hasegawa JT. The burden of critical limb ischemia: a review of recent literature.Vasc Health Risk Manag. 2019; 15:187–208. doi: 10.2147/VHRM.S209241CrossrefMedlineGoogle Scholar3.